JP2023515845A - 抗－ｃｄ５６抗体－薬物複合体およびその治療での使用 - Google Patents

抗－ｃｄ５６抗体－薬物複合体およびその治療での使用 Download PDF

Info

Publication number
JP2023515845A
JP2023515845A JP2022552310A JP2022552310A JP2023515845A JP 2023515845 A JP2023515845 A JP 2023515845A JP 2022552310 A JP2022552310 A JP 2022552310A JP 2022552310 A JP2022552310 A JP 2022552310A JP 2023515845 A JP2023515845 A JP 2023515845A
Authority
JP
Japan
Prior art keywords
antibody
drug conjugate
mmae
less
represented
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022552310A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023515845A5 (https=
Inventor
ルドヴィク ジュエン，
クリスティーヌ バルチュス，
オドレイ デグランジュ，
アントワーヌ トウゼ，
ティボー ケルヴァレック，
ヴァレリー ルブロン，
マータブ サミミ，
Original Assignee
エムセーエスアーエフ インサイド オンコロジー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エムセーエスアーエフ インサイド オンコロジー filed Critical エムセーエスアーエフ インサイド オンコロジー
Publication of JP2023515845A publication Critical patent/JP2023515845A/ja
Publication of JP2023515845A5 publication Critical patent/JP2023515845A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6865—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from skin, nerves or brain cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2022552310A 2020-02-27 2021-02-26 抗－ｃｄ５６抗体－薬物複合体およびその治療での使用 Pending JP2023515845A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR2001974A FR3107648B1 (fr) 2020-02-27 2020-02-27 conjugués anticorps-médicament anti-CD56 et leur utilisation en thérapie
FR2001974 2020-02-27
PCT/FR2021/050332 WO2021170961A1 (fr) 2020-02-27 2021-02-26 Conjugués anticorps-médicament anti-cd56 et leur utilisation en thérapie

Publications (2)

Publication Number Publication Date
JP2023515845A true JP2023515845A (ja) 2023-04-14
JP2023515845A5 JP2023515845A5 (https=) 2024-02-22

Family

ID=71894885

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022552310A Pending JP2023515845A (ja) 2020-02-27 2021-02-26 抗－ｃｄ５６抗体－薬物複合体およびその治療での使用

Country Status (8)

Country Link
US (2) US20230144142A1 (https=)
EP (1) EP4110405A1 (https=)
JP (1) JP2023515845A (https=)
CN (1) CN115515642A (https=)
AU (1) AU2021227413A1 (https=)
CA (1) CA3166699A1 (https=)
FR (1) FR3107648B1 (https=)
WO (1) WO2021170961A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3096259B1 (fr) * 2019-05-20 2023-12-15 Mc Saf conjugués anticorps-médicament et leur utilisation en thérapie
FR3131835B1 (fr) * 2022-01-17 2025-11-21 Mc Saf Procédé de préparation de conjugués anticorps-médicament
FR3131836B1 (fr) * 2022-01-17 2025-05-23 Mc Saf Conjugués anticorps-médicament pour utilisation thérapeutique
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
AU2024279278A1 (en) 2023-05-31 2025-12-18 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025149947A1 (en) * 2024-01-12 2025-07-17 Seagen Inc. Antibody-drug conjugates
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016531094A (ja) * 2013-07-11 2016-10-06 ユニヴェルシテ フランソワ ラブレーＵｎｉｖｅｒｓｉｔｅ Ｆｒａｎｃｏｉｓ Ｒａｂｅｌａｉｓ 新規の抗体−薬剤コンジュゲート及び治療におけるその使用
JP2019034948A (ja) * 2012-05-21 2019-03-07 ジェネンテック， インコーポレイテッド 血液脳関門輸送の安全性を改善するための方法
US20190209702A1 (en) * 2018-01-08 2019-07-11 Regeneron Pharmaceuticals, Inc. Steroids and antibody-conjugates thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104640572B (zh) * 2012-05-15 2018-04-27 索伦托医疗有限公司 药物偶联物，偶联方法，及其用途
US10548987B2 (en) 2015-07-31 2020-02-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibody-drug conjugates for targeting CD56-positive tumors
CN107744592B (zh) * 2017-09-15 2020-04-28 四川大学 抗cd56抗体与海兔毒素偶联复合物及其制备方法和用途
CN107715119B (zh) * 2017-09-15 2020-11-10 四川大学 抗cd56抗体与多卡霉素偶联复合物及其制备方法和用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019034948A (ja) * 2012-05-21 2019-03-07 ジェネンテック， インコーポレイテッド 血液脳関門輸送の安全性を改善するための方法
JP2016531094A (ja) * 2013-07-11 2016-10-06 ユニヴェルシテ フランソワ ラブレーＵｎｉｖｅｒｓｉｔｅ Ｆｒａｎｃｏｉｓ Ｒａｂｅｌａｉｓ 新規の抗体−薬剤コンジュゲート及び治療におけるその使用
US20190209702A1 (en) * 2018-01-08 2019-07-11 Regeneron Pharmaceuticals, Inc. Steroids and antibody-conjugates thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MABS, vol. 8, no. 4, JPN6024045984, 2016, pages 799 - 810, ISSN: 0005603496 *

Also Published As

Publication number Publication date
US20230144142A1 (en) 2023-05-11
WO2021170961A1 (fr) 2021-09-02
FR3107648B1 (fr) 2022-03-18
FR3107648A1 (fr) 2021-09-03
EP4110405A1 (fr) 2023-01-04
AU2021227413A1 (en) 2022-10-20
US20230405140A1 (en) 2023-12-21
CA3166699A1 (fr) 2021-09-02
CN115515642A (zh) 2022-12-23

Similar Documents

Publication Publication Date Title
JP2023515845A (ja) 抗－ｃｄ５６抗体－薬物複合体およびその治療での使用
CA3082160C (en) Anti-mesothelin antibody and antibody drug conjugate thereof
JP7374891B2 (ja) 活性化可能抗ｃｄ７１抗体による薬物コンジュゲート及びこの使用の方法
JP2021513844A (ja) グリピカン３抗体およびそのコンジュゲート
KR20180016724A (ko) Cd123 항체 및 이의 접합체
RS62157B1 (sr) Anti-her2 antitelo i njegov konjugat
US10112999B2 (en) Anti-PRLR antibody-drug conjugates (ADC) and uses thereof
JP2022533854A (ja) 抗体－薬物コンジュゲート、及び、治療におけるその使用
JP2025509152A (ja) 抗ＣａｎＡｇ抗体複合体
CN119948062A (zh) 靶向napi2b的抗体-药物缀合物及其使用方法
KR20250137203A (ko) 항체 약물 접합체
CN119604314A (zh) 抗gd2抗体、免疫偶联物及其治疗用途
CN113453724B (zh) 基于磺酰基马来酰亚胺的连接子和相应的偶联物
CN107849146A (zh) 卡奇霉素构建体和使用方法
JP2025109708A (ja) Ｂリンパ球特異的アマトキシン抗体コンジュゲート
EP4491632A1 (en) Ror1-targeted binding molecule and use thereof
WO2025185559A1 (zh) 抗FGFR2b抗体、其抗体药物偶联物及其用途
TW202600175A (zh) 用於治療gd2陽性癌症之抗gd2抗體及免疫結合物
HK40123391A (zh) 抗gd2抗体、免疫偶联物及其治疗用途
WO2026082125A1 (zh) 结合folr1的抗体、含有其的药物及其应用
BR112016018005B1 (pt) Conjugados anticorpo-droga e imunotoxinas

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240213

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240213

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20241115

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241119

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250527